"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
| Descriptor ID |
D002945
|
| MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
| Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 3 | 5 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 4 | 4 |
| 2002 | 1 | 2 | 3 |
| 2003 | 4 | 3 | 7 |
| 2004 | 4 | 5 | 9 |
| 2005 | 1 | 3 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 2 | 7 | 9 |
| 2008 | 6 | 6 | 12 |
| 2009 | 0 | 4 | 4 |
| 2010 | 2 | 6 | 8 |
| 2011 | 2 | 6 | 8 |
| 2012 | 1 | 4 | 5 |
| 2013 | 5 | 4 | 9 |
| 2014 | 3 | 6 | 9 |
| 2015 | 5 | 8 | 13 |
| 2016 | 3 | 4 | 7 |
| 2017 | 2 | 2 | 4 |
| 2018 | 6 | 1 | 7 |
| 2019 | 9 | 3 | 12 |
| 2020 | 0 | 6 | 6 |
| 2021 | 2 | 6 | 8 |
| 2022 | 1 | 3 | 4 |
| 2023 | 1 | 8 | 9 |
| 2024 | 5 | 5 | 10 |
| 2025 | 3 | 4 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
Dual-function polyester nanoparticles for amplified anti-inflammatory effects. Sci Adv. 2025 Aug 08; 11(32):eadw1358.
-
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer. J Clin Oncol. 2025 Aug 10; 43(23):2559-2565.
-
Understanding Hydronephrosis Occurrence by an Individual-Kidney Level Analysis of all Events Postchemoradiation Therapy for Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2025 Oct 01; 123(2):513-522.
-
Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy. J Clin Oncol. 2025 Jul; 43(19):2173-2183.
-
Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial. Pediatr Blood Cancer. 2025 Jun; 72(6):e31680.
-
Real-World Experience Using Sodium Thiosulfate Pentahydrate Off-Label for Cisplatin Otoprotection in Children, Adolescents, and Young Adults. Pediatr Blood Cancer. 2025 May; 72(5):e31631.
-
Regulating chemoresistance and cancer stemness: the CDH17-YAP pathway in distinct cellular states of lung cancer CTC clusters. Cell Mol Biol Lett. 2025 Feb 24; 30(1):23.
-
Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res. 2025 Jan 17; 31(2):258-265.
-
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline. J Clin Oncol. 2025 Feb 10; 43(5):605-615.
-
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. J Clin Oncol. 2025 Feb 10; 43(5):536-544.